Tag: Cancer: Lung
Models Project 79 Percent Drop in Lung CA Mortality by 2065
Annual number of deaths expected to continue to decrease despite growth, aging of U.S. population
Angiotensin-Converting Enzyme Inhibitors May Up Lung CA Risk
Higher risk seen with ACEIs versus angiotensin receptor blockers; risk linked to duration of use
Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA
Both overall and progression-free survival longer with durvalumab than with placebo
Thermal Ablation Acceptable for Early Lung Cancer
Regarding overall survival, thermal ablation non-inferior to radiation for primary treatment
Plasma-Based Genotyping Aids Targeted Tx of Metastatic NSCLC
Most patients who received targeted therapy based on plasma result achieved clinical response
In NSCLC, Longer Survival With Brigatinib Than Crizotinib
Longer progression-free survival in those with ALK-positive dz who did not previously take ALK inhibitor
Integrated Classifier Identifies Benign Lung Nodules
Classifier integrates relative abundance of two plasma proteins with clinical risk prediction model
Poor Shared Decision-Making for Lung Cancer Screening
Physicians universally recommended screening, with almost no discussion of harms
Broad Genetic Testing for NSCLC May Not Improve Survival
Compared with routine genetic testing, no improvement seen in unadjusted mortality rate
Biomarker Panel May Improve Lung Cancer Risk Assessment
Risk score based on panel of four circulating protein biomarkers
